EE200100689A - IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon - Google Patents

IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon

Info

Publication number
EE200100689A
EE200100689A EEP200100689A EEP200100689A EE200100689A EE 200100689 A EE200100689 A EE 200100689A EE P200100689 A EEP200100689 A EE P200100689A EE P200100689 A EEP200100689 A EE P200100689A EE 200100689 A EE200100689 A EE 200100689A
Authority
EE
Estonia
Prior art keywords
treatment
medicament
preparation
pharmaceutical composition
neurological diseases
Prior art date
Application number
EEP200100689A
Other languages
English (en)
Inventor
Revel Michel
Chebath Judith
Pizzi Marina
Spano Pierfranco
Boschert Ursula
Original Assignee
Yeda Research And Development Co. Ltd.
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd., Applied Research Systems Ars Holding N.V. filed Critical Yeda Research And Development Co. Ltd.
Publication of EE200100689A publication Critical patent/EE200100689A/et
Publication of EE05559B1 publication Critical patent/EE05559B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200100689A 1999-06-21 2000-06-21 IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks EE05559B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13058699A IL130586A0 (en) 1999-06-21 1999-06-21 IL6RIL6 chimera for the treatment of demyelinating diseases
PCT/IL2000/000363 WO2000078331A2 (en) 1999-06-21 2000-06-21 Il6ril6 chimera for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EE200100689A true EE200100689A (et) 2003-02-17
EE05559B1 EE05559B1 (et) 2012-08-15

Family

ID=11072949

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100689A EE05559B1 (et) 1999-06-21 2000-06-21 IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks

Country Status (20)

Country Link
US (1) US7201896B1 (et)
EP (1) EP1185293B1 (et)
JP (1) JP4846148B2 (et)
KR (1) KR100678290B1 (et)
CN (1) CN1164328C (et)
AT (1) ATE306280T1 (et)
AU (1) AU778662B2 (et)
BR (1) BR0011363A (et)
CA (1) CA2374997C (et)
DE (1) DE60023139T2 (et)
DK (1) DK1185293T3 (et)
EA (1) EA004626B1 (et)
EE (1) EE05559B1 (et)
ES (1) ES2250140T3 (et)
IL (2) IL130586A0 (et)
MX (1) MXPA02000116A (et)
NO (1) NO329028B1 (et)
UA (1) UA76695C2 (et)
WO (1) WO2000078331A2 (et)
ZA (1) ZA200109488B (et)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317273B1 (en) 2000-09-14 2006-05-03 Ares Trading S.A. Use of il-6r/il-6 chimera in huntington's disease
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
EP1386155A4 (en) * 2001-04-10 2006-05-10 Univ Leland Stanford Junior THERAPEUTIC AND DIAGNOSTIC USE OF ANTIBODY SPECIFICITY PROFILES
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1631662A1 (en) * 2003-06-12 2006-03-08 Yeda Research & Development Company, Ltd. Enhancement of oligodendrocyte differentiation
EP1692273A1 (en) * 2003-11-14 2006-08-23 Mats J. Olsson Melanocytes in therapy of neurodegenerative diseases
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CN108778121A (zh) * 2016-02-12 2018-11-09 Als治疗发展研究所 基于动力学数据评估als病情进展
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JPH1148413A (ja) 1997-08-06 1999-02-23 Dainippon Printing Co Ltd ホルムアルデヒド捕捉壁紙およびその製造方法
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤

Also Published As

Publication number Publication date
ZA200109488B (en) 2002-11-18
KR100678290B1 (ko) 2007-02-05
CN1164328C (zh) 2004-09-01
EA004626B1 (ru) 2004-06-24
BR0011363A (pt) 2002-02-26
ATE306280T1 (de) 2005-10-15
DE60023139T2 (de) 2006-05-04
JP4846148B2 (ja) 2011-12-28
HK1047549A1 (en) 2003-02-28
ES2250140T3 (es) 2006-04-16
KR20020013901A (ko) 2002-02-21
US7201896B1 (en) 2007-04-10
WO2000078331A3 (en) 2001-07-05
NO20015673D0 (no) 2001-11-20
JP2003502382A (ja) 2003-01-21
NO329028B1 (no) 2010-08-02
EE05559B1 (et) 2012-08-15
UA76695C2 (uk) 2006-09-15
AU5423100A (en) 2001-01-09
AU778662B2 (en) 2004-12-16
IL130586A0 (en) 2000-06-01
WO2000078331A2 (en) 2000-12-28
IL147188A (en) 2015-09-24
DE60023139D1 (de) 2006-02-23
EP1185293B1 (en) 2005-10-12
CA2374997C (en) 2010-04-13
CN1364088A (zh) 2002-08-14
EP1185293A2 (en) 2002-03-13
EA200200063A1 (ru) 2002-06-27
NO20015673L (no) 2001-12-17
DK1185293T3 (da) 2005-12-27
MXPA02000116A (es) 2003-07-21
CA2374997A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
PT946157E (pt) Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
EE05559B1 (et) IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
UA83988C2 (ru) Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160621